

This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

October 17, 2024

To whom it may concern:

Company	D.Western Therapeutics Institute, Inc.
Representative	Yuichi Hidaka, President and CEO (Code No. 4576)
Contact	Sayako Matsubara, Director
TEL	052-218-8785

Conclusion of a joint research agreement with the University of Tokyo on glaucoma surgery

We are pleased to announce that D.Western Therapeutics Institute, Inc. ("DWTI") and the University of Tokyo have decided to enter into a joint research agreement today to research and develop new treatments for glaucoma surgery.

The first treatment for glaucoma is the administration of eye drops, but if the drops are ineffective or depending on the progression of the disease, laser treatment or glaucoma surgery may be performed. Glaucoma surgery not only has the potential to cause severe complications after the surgery, but there is also no guarantee that it will be effective, as the intraocular pressure may continue to be unstable after the surgery, or the patient may require further surgery due to age-related functional failure.

DWTI, Atsushi Miyajima, a project professor at the Institute for Quantitative Biosciences at the University of Tokyo, and Makoto Aihara, a professor at the Department of Ophthalmology at the Graduate School of Medicine and Faculty of Medicine at the University of Tokyo, will be conducting joint research aimed at developing a revolutionary new eye drop for glaucoma surgery.

We are focusing on the ophthalmology field, and in particular, we have our ophthalmic solutions (GLANATEC® and GLA-ALPHA®) for glaucoma on the market and are also developing H-1337 in the United States. We believe that advancing research into treatments related to glaucoma surgery will provide glaucoma patients with various treatment options. We will continue this joint research to expand our pipeline further.

There will be no change to the earnings forecast for the fiscal year ending December 2024 as a result of this matter.

End